ARIADNE Clinical Trial for Persistent Atrial Fibrillation
This study, called ARIADNE, is testing different ways to perform a catheter ablation procedure for people with persistent atrial fibrillation (AF). Catheter ablation is a procedure that uses energy to create small scars in the heart to block faulty electrical signals that cause AF. In this study, doctors will use a special catheter (a thin, flexible tube) that can switch between two types of energy: radiofrequency ablation (RFA) and pulsed field ablation (PFA). You would be randomly assigned to one of three ablation strategies. The main goal is to see how many people are free from AF after 12 months. To join, you must be between 18 and 80 years old, have symptomatic persistent AF, and be a suitable candidate for catheter ablation. The current recruitment status is unclear.
- Study design
- This is a randomized study with about 60 participants. You would be assigned to one of three different ablation strategies.
- What's involved
- You would undergo a catheter ablation procedure. An implantable loop recorder will be placed to continuously monitor your heart rhythm.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your heart rhythm will be monitored for 12 months after the procedure to see if the treatment was successful.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
ARIADNE Clinical Trial
At a glance
Conditions
NCT06747091
Where you'd take part
This study runs at 3 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Kristie Coleman
New York, New Yorkstudy coordinator listed
Recruiting
Long Island Jewish Medical Center
New Hyde Park, New Yorkstudy coordinator listed
Recruiting
North Shore University Hospital
Manhasset, New Yorkstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Stavros Mountantonakis, MD · PRINCIPAL_INVESTIGATOR · Northwell Health
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Percent of subjects free from primary effectiveness failure12 Months
The primary effectiveness endpoint is freedom from documented recurrence of AF, atrial tachycardia (AT), or atrial flutter (AFL) lasting \>2 minutes based on electrocardiographic data through 12-month follow-up and excluding a 60-day blanking period.